Pay in 4 interest-free payments of $6.29 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
Payers are starting to expand coverage criteria as real-world outcomes and employer demand for obesity care increases
Protein-forward recommendations tailored to your preferences and dietary needs
Singh AP, Singh M, Balakumar P
Walker RF
US$ 21.00
US$ 28.16
US$ 23.98
US$ 27.17
US$ 21.20
US$ 28.76
US$ 27.64
US$ 28.46
US$ 26.17
US$ 24.40
